Pharmaceutical Contract Development & Manufacturing Market by Service (Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services), End User (Big Pharma, Generic Pharmaceutical Companies, Small & Mid-Size Pharma) -

Pharmaceutical Contract Development & Manufacturing Market by Service (Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services), End User (Big Pharma, Generic Pharmaceutical Companies, Small & Mid-Size Pharma) - Global Forecast 2024-2030

The Pharmaceutical Contract Development & Manufacturing Market size was estimated at USD 125.73 billion in 2023 and expected to reach USD 136.27 billion in 2024, at a CAGR 8.46% to reach USD 222.04 billion by 2030.

Pharmaceutical contract development and manufacturing (CDMO) refers to outsourcing drug development and manufacturing processes to third-party organizations. CDMO services cover a broad range of activities, including drug discovery, formulation development, process optimization, scale-up, regulatory submission support, and the eventual manufacturing of the final product for clinical trials or commercial distribution. Pharmaceutical companies can concentrate on their core competencies, such as drug discovery and marketing, by outsourcing to CDMOs while gaining access to cutting-edge technologies and regulatory expertise. The applications for contract development and manufacturing span the entire lifecycle of pharmaceutical products. The increasing trend of pharmaceutical outsourcing due to cost reduction and efficiency gains and expanding pipelines of biopharmaceutical companies requiring specialized manufacturing capabilities have increased the demand for pharmaceutical contract development and manufacturing. In addition, the globalization of the pharmaceutical industry drives the need for local manufacturing facilities to navigate regulatory landscapes, developing a growing need for pharmaceutical contract development and manufacturing services. However, regulatory challenges and compliance costs associated with varying international standards and complexities in supply chain management and logistics can negatively affect the pharmaceutical contract development and manufacturing market. Nevertheless, the emergence of personalized medicine and next-generation therapies creates opportunities for pharmaceutical contract development and manufacturing. Moreover, investments by vendors in advanced manufacturing technologies such as continuous manufacturing and single-use systems are expected to make pharmaceutical contract development and manufacturing an attractive option for end-users.

Regional Insights

Asia-Pacific is a rapidly growing market for pharmaceutical contract development and manufacturing organizations (CDMOs) fueled by increasing healthcare expenditure and supportive government policies. The emerging economies in the Asia-Pacific are investing heavily in biotechnology and are known for their generic pharmaceutical manufacturing capabilities. China's Made in China 2025 plan and India's government aim to advance their domestic pharmaceutical sectors, influencing CDMO activities in the Asia-Pacific. The Americas region is a maturing market for pharmaceutical CDMOs characterized by high spending on health services, extensive R&D activities, and many biotechnology and pharmaceutical companies. Consumers in the Americas expect high-quality products, prioritizing regulatory compliance. This has led CDMOs to invest in advanced manufacturing technologies and capabilities to cater to these market needs. The European Union is a significant hub for high-quality pharmaceutical manufacturing and innovation. A strong emphasis on quality and compliance with Good Manufacturing Practice (GMP) standards has improved access to various advanced drug modalities. Recent patents in the EMEA region are focused on pharmaceutical formulations and advanced delivery systems. The Middle East and parts of Africa are emerging markets with increasing investment in healthcare infrastructure and a growing demand for pharmaceutical products.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Pharmaceutical Contract Development & Manufacturing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising Demand for Generics and Biological Therapies
    • Increasing Investments in Pharmaceutical R&D
    • Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
    • Market Restraints
      • Introduction of Serialization
      • Market Opportunities
        • Increasing Focus on Nuclear Medicine and Specialty Drugs
        • Growing need for Cell and Gene Therapies
        • Market Challenges
          • Variable Trade Policies Between Countries
          • Market Segmentation Analysis
            • Service: Rising penetration of biologics manufacturing services by end-users to adhere to stringent regulatory standards
            • End User: Big pharma companies widely adopting pharmaceutical CDMO services to manage complex drug development
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pharmaceutical Contract Development & Manufacturing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pharmaceutical Contract Development & Manufacturing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Alcami Announces Acquisition of West-Coast-Based Pacific Pharmaceutical Services
              
              Alcami Corporation acquired Pacific Pharmaceutical Services, Inc. (PPS), markedly enhancing its storage and service capabilities. This strategic move, part of a deliberate effort to reinforce Alcami's footprint, harnesses PPS's proficiency in comprehensive Good Manufacturing Practices (cGMP) pharmaceutical storage and services, notably augmenting its presence on the West Coast.
              
              Piramal Pharma to Invest INR 1,000 Crore for Expansion
              
              Piramal Pharma Ltd. announced a significant investment initiative, earmarking approximately INR 1,000 crore for the next year and a half. This capital infusion aims to streamline production capabilities through focused brownfield expansions. This financial commitment aims to enhance revenue streams, drive operational efficiency, and optimize the productivity of newly augmented brownfield sites.
              
              eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
              
              eXmoor Pharma achieved a significant milestone with the inauguration of its state-of-the-art Cell and Gene Therapy Centre, a 65,000-square-foot good manufacturing practice facility. This new facility in Bristol is a testament to eXmoor's 19-year legacy in translation consulting and process development and is designed to propel clinical trials and subsequent stages of CGT. Furthermore, the facility mirrors eXmoor's commitment to delivering advanced production solutions for cell and gene therapies while prioritizing environmental responsibility.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pharmaceutical Contract Development & Manufacturing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Pharmaceutical Contract Development & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Aenova Holding GmbH, Almac Group Limited, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Curia Global, Inc., Danaher Corporation, Delwis Healthcare Pvt. Ltd., Evonik Industries AG, Fabbrica Italiana Sintetici S.p.A., Famar Health Care Services, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Grifols S.A., Jubilant Pharmova Limited, Lonza Group AG, Pfizer Inc., Recipharm AB, Samsung Biologics Co., Ltd., Siegfried AG, The Fareva Group, Thermo Fisher Scientific Inc., Vetter Pharma-Fertigung GmbH & Co. KG, and WuXi Biologics Co., Ltd..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Pharmaceutical Contract Development & Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Service
              • Biologics Manufacturing Services
                • Biologics API Manufacturing Services
                • Biologics FDF Manufacturing Services
                • Drug Development Services
                • Pharmaceutical Manufacturing Services
                  • Pharmaceutical API Manufacturing
                    • Capsule Manufacturing Services
                    • Oral Liquid Manufacturing Services
                    • Parenteral/Injectable Manufacturing Services
                    • Tablet Manufacturing Services
                    • Pharmaceutical FDF Manufacturing
                    • Secondary Packaging Services
                    • End User
                      • Big Pharma
                      • Generic Pharmaceutical Companies
                      • Small & Mid-Size Pharma
                      • Region
                        • Americas
                          • Argentina
                          • Brazil
                          • Canada
                          • Mexico
                          • United States
                            • California
                            • Florida
                            • Illinois
                            • New York
                            • Ohio
                            • Pennsylvania
                            • Texas
                            • Asia-Pacific
                              • Australia
                              • China
                              • India
                              • Indonesia
                              • Japan
                              • Malaysia
                              • Philippines
                              • Singapore
                              • South Korea
                              • Taiwan
                              • Thailand
                              • Vietnam
                              • Europe, Middle East & Africa
                                • Denmark
                                • Egypt
                                • Finland
                                • France
                                • Germany
                                • Israel
                                • Italy
                                • Netherlands
                                • Nigeria
                                • Norway
                                • Poland
                                • Qatar
                                • Russia
                                • Saudi Arabia
                                • South Africa
                                • Spain
                                • Sweden
                                • Switzerland
                                • Turkey
                                • United Arab Emirates
                                • United Kingdom
                                
                                
                                Please Note: PDF & Excel + Online Access - 1 Year